U.S. License Holder:
Date of License:
ELITEK (rasburicase) is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
5,919,651 (Expression of Polypeptides in Yeast)
Genentech, Inc.; Washington Research Foundation
Sanofi; Sanofi-Synthelabo LLC; Synthelabo LLC; Sanofi-Aventis US LLC
Federal Circuit Appeal(s)
Summary Judgment of Noninfringement Granted; Federal Circuit Appeal Voluntarily Dismissed